ici 118551 and Disease Exacerbation

ici 118551 has been researched along with Disease Exacerbation in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Branca, C; Caccamo, A; Hartman, LK; Oddo, S; Wisely, EV	1

Other Studies

1 other study(ies) available for ici 118551 and Disease Exacerbation

Article	Year
Administration of a selective β2 adrenergic receptor antagonist exacerbates neuropathology and cognitive deficits in a mouse model of Alzheimer's disease. Neurobiology of aging, 2014, Volume: 35, Issue:12 Topics: Adrenergic beta-2 Receptor Antagonists; Alzheimer Disease; Amyloid beta-Peptides; Animals; Cerebral Cortex; Cognition; Disease Models, Animal; Disease Progression; Female; Hippocampus; Male; Mice, Transgenic; Phosphorylation; Propanolamines; Receptors, Adrenergic, beta-2; tau Proteins	2014

Article

Year

Administration of a selective β2 adrenergic receptor antagonist exacerbates neuropathology and cognitive deficits in a mouse model of Alzheimer's disease.

Neurobiology of aging, 2014, Volume: 35, Issue:12

Topics: Adrenergic beta-2 Receptor Antagonists; Alzheimer Disease; Amyloid beta-Peptides; Animals; Cerebral Cortex; Cognition; Disease Models, Animal; Disease Progression; Female; Hippocampus; Male; Mice, Transgenic; Phosphorylation; Propanolamines; Receptors, Adrenergic, beta-2; tau Proteins

2014